Prof. Dr. Med. Matthias Guckenberger, University Hospital, Zurich

Bio
Matthias Guckenberger (MG) is Chairman of the Department of Radiation Oncology and full Professor at the University Hospital Zurich and University of Zurich. He serves on the Board of Directors of the European Society for Radiation Oncology (ESTRO) and is member of the EORTC Radiation Oncology Science Council. His clinical and research focus is image-guided high-precision radiotherapy, especially for lung cancer, prostate cancer and oligometastatic disease. His work is published in > 350 Pubmed listed articles resulting in a h-index of 59 and two patents. The scientific achievements have been acknowledged with several national and international awards, most recently as “Honorary Physicist” by the ESTRO society in 2019.

Presentation
Radiotherapy is key in the treatment of stage III NSCLC

Matthias Guckenberger

The introduction of immune checkpoint inhibition has revolutionized the treatment of localized NSCLC, for both patients with resectable and unresectable NSCLC. In patients with resectable NSCLC, the evidence and clinical practice is going into the direction of a neoadjuvant or perioperative approach. Despite resectability has been defined upfront before any anti-cancer treatment, a strategy of converting borderline or even unresectable patients by neoadjuvant treatment into resectable patients is more and more practiced and advertised.

This presentation will illustrate the concerns of such a “conversion” strategy and will simultaneously highlight the current status and progress of combined modality treatment using radiotherapy as local modality.